Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023

Wednesday, July 28, 2010 1 min read

Key Takeaway: Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023

Full Press Release Details

Astellas to Pay $295 Million to Extend License of Regeneron's VelocImmune® Antibody Technology through 2023.